Crohn's Disease

Categories: Gastrointestinal diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Crohn's Disease

MalaCards integrated aliases for Crohn's Disease:

Name: Crohn's Disease 12 73 20 43 6 42 15 37 17
Crohn Disease 12 43 36 6 15 70
Pediatric Crohn's Disease 12 20 70
Enteritis 20 54 70
Crohn's Disease of Large Bowel 12 70
Enteritis, Granulomatous 43 6
Granulomatous Colitis 12 20
Ileitis 20 70
Pediatric Onset Crohn's Disease 20
Crohn's Disease, Pediatric 20
Crohn's Disease of Colon 12
Granulomatous Enteritis 20
Colitis, Granulomatous 43
Enteritis, Regional 43
Regional Enteritis 70
Crohn's Enteritis 43


External Ids:

Disease Ontology 12 DOID:8778
KEGG 36 H00286
ICD9CM 34 555.1
MeSH 44 D003424
NCIt 50 C37262
SNOMED-CT 67 7620006
UMLS 70 C0010346 C0014335 C0020877 more

Summaries for Crohn's Disease

MedlinePlus : 42 What is Crohn's disease? Crohn's disease is a chronic disease that causes inflammation in your digestive tract. It can affect any part of your digestive tract, which runs from your mouth to your anus. But it usually affects your small intestine and the beginning of your large intestine. Crohn's disease is an inflammatory bowel disease (IBD). Ulcerative colitis and microscopic colitis are other common types of IBD. What causes Crohn's disease? The cause of Crohn's disease is unknown. Researchers think that an autoimmune reaction may be one cause. An autoimmune reaction happens when your immune system attacks healthy cells in your body. Genetics may also play a role, since Crohn's disease can run in families. Stress and eating certain foods don't cause the disease, but they can make your symptoms worse. Who is at risk for Crohn's disease? There are certain factors which can raise your risk of Crohn's disease: Family history of the disease. Having a parent, child, or sibling with the disease puts you at higher risk. Smoking. This may double your risk of developing Crohn's disease. Certain medicines, such as antibiotics, birth-control pills, and nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen. These may slightly increase your chance of developing Crohn's. A high-fat diet. This may also slightly increase your risk of Crohn's. What are the symptoms of Crohn's disease? The symptoms of Crohn's disease can vary, depending where and how severe your inflammation is. The most common symptoms include Diarrhea Cramping and pain in your abdomen Weight loss Some other possible symptoms are Anemia, a condition in which you have fewer red blood cells than normal Eye redness or pain Fatigue Fever Joint pain or soreness Nausea or loss of appetite Skin changes that involve red, tender bumps under the skin Stress and eating certain foods such as carbonated drinks and high-fiber foods may make some people's symptoms worse. What other problems can Crohn's disease cause? Crohn's disease can cause other problems, including Intestinal obstruction, a blockage in the intestine Fistulas, abnormal connections between two parts inside of the body Abscesses, pus-filled pockets of infection Anal fissures, small tears in your anus that may cause itching, pain, or bleeding Ulcers, open sores in your mouth, intestines, anus, or perineum Malnutrition, when your body does not get the right amount of vitamins, minerals, and nutrients it needs Inflammation in other areas of your body, such as your joints, eyes, and skin How is Crohn's disease diagnosed? To make a diagnosis, your health care provider Will ask about your family history and medical history Will ask about your symptoms Will do a physical exam, including Checking for bloating in your abdomen Listening to sounds within your abdomen using a stethoscope Tapping on your abdomen to check for tenderness and pain and to see if your liver or spleen is abnormal or enlarged May do various tests, including Blood and stool tests A colonoscopy An upper GI endoscopy, a procedure in which your provider uses a scope to look inside your mouth, esophagus, stomach, and small intestine Diagnostic imaging tests, such as a CT scan or an upper GI series. An upper GI series uses a special liquid called barium and x-rays. Drinking the barium will make your upper GI tract more visible on an x-ray. What are the treatments for Crohn's disease? There is no cure for Crohn's disease, but treatments can decrease the inflammation in your intestines, relieve symptoms, and prevent complications. Treatments include medicines, bowel rest, and surgery. No single treatment works for everyone. You and your health care provider can work together to figure out which treatment is best for you: Medicines for Crohn's include various medicines that decrease the inflammation. Some of these medicines do this by reducing the activity of your immune system. Medicines can also help with symptoms or complications, such as nonsteroidal anti-inflammatory drugs and anti-diarrheal medicines. If your Crohn's causes an infection, you may need antibiotics. Bowel rest involves drinking only certain liquids or not eating or drinking anything. This allows your intestines to rest. You may need to do this if your Crohn's disease symptoms are severe. You get your nutrients through drinking a liquid, a feeding tube, or an intravenous (IV) tube. You may need to do bowel rest in the hospital, or you may be able to do it at home. It will last for a few days or up to several weeks. Surgery can treat complications and reduce symptoms when other treatments are not helping enough. The surgery will involve removing a damaged part of your digestive tract to treat Fistulas Bleeding that is life threatening Intestinal obstructions Side effects from medicines when they threaten your health Symptoms when medicines do not improve your condition Changing your diet can help reduce symptoms. Your provider may recommend that you make changes to your diet, such as Avoiding carbonated drinks Avoiding popcorn, vegetable skins, nuts, and other high-fiber foods Drinking more liquids Eating smaller meals more often Keeping a food diary to help identify foods that cause problems Some people also need go on special diet, such as a low-fiber diet. National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Crohn's Disease, also known as crohn disease, is related to inflammatory bowel disease and ulcerative colitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Crohn's Disease is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are NOD-like receptor signaling pathway and Cytokine-cytokine receptor interaction. The drugs Norepinephrine and Atracurium have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 An intestinal disease that involves inflammation located in intestine.

MedlinePlus Genetics : 43 Crohn disease is a complex, long-lasting (chronic) disorder that primarily affects the digestive system. This condition involves an abnormal immune response that causes excess inflammation. It most often affects the intestinal walls, particularly in the lower part of the small intestine (the ileum) and portions of the large intestine (the colon). However, inflammation can occur in any part of the digestive system, from the mouth to the anus. The inflamed tissues become thick and swollen, and the inner surfaces of the digestive system may develop open sores (ulcers).Crohn disease most commonly appears in a person's late teens or twenties, although the disease can begin at any age. Signs and symptoms tend to flare up multiple times throughout life. The most common features of this condition are persistent diarrhea, abdominal pain and cramping, loss of appetite, weight loss, and fever. Some people with Crohn disease have blood in the stool from inflamed tissues in the intestine; over time, chronic bleeding can lead to a low number of red blood cells (anemia). In some cases, Crohn disease can also cause inflammation affecting the joints, eyes, or skin.Intestinal blockage is a common complication of Crohn disease. Blockages are caused by swelling or a buildup of scar tissue in the intestinal walls. Some affected individuals also develop fistulae, which are abnormal connections between the intestine and other tissues. Fistulae occur when ulcers break through the intestinal wall and passages form between loops of the intestine or between the intestine and nearby structures (such as the bladder, vagina, or skin).Crohn disease is one common form of inflammatory bowel disease (IBD). Another type of IBD, ulcerative colitis, also causes chronic inflammation of the intestinal lining. Unlike Crohn disease, which can affect any part of the digestive system, ulcerative colitis typically causes inflammation only in the colon.

GARD : 20 Crohn's disease is a type of inflammatory bowel disease (IBD), the general name for conditions that cause inflammation in the gastrointestinal (GI) tract. Common signs and symptoms include abdominal pain and cramping, diarrhea, and weight loss. Other general symptoms include feeling tired, nausea and loss of appetite, fever, and anemia. Complications of Crohn's disease may include intestinal blockage, fistulas, anal fissures, ulcers, malnutrition, and inflammation in other areas of the body. Crohn's disease can occur in people of all age groups but is most often diagnosed in young adults. The exact cause is unknown, but is thought to be due from a combination of certain genetic variations, changes in the immune system, and the presence of bacteria in the digestive tract. Many of the major genes related to Crohn disease, including NOD2, ATG16L1, IL23R, and IRGM, are involved in immune system function. The disease is not inherited but it appears to run in some families because in about 15% of the cases the disease is present in more than one relative. Treatment is aimed at relieving symptoms and reducing inflammation, and may include diet and medication, but some people require surgery. Surgery often involves removal of the diseased segment of bowel (resection), the two ends of healthy bowel are then joined together (anastomosis). In about 30% of people who have surgery for Crohn's disease symptoms may come back within three years and up to 60% will have recurrence within ten years.

KEGG : 36 Crohn disease is a chronic, relapsing inflammatory bowel disease characterized by granulomatous inflammation, primarily localized to the terminal ileum. Most patients have involvement of the small intestine, but the other area of gastrointestinal tract may also be affected. In Western populations, over 50% of patients possess NOD2 mutations. Evidence exists that the NOD2 polymorphisms impair NF-kappaB activation and cytokine secretion in response to its ligand. The pathogenesis of Crohn's disease is also attributed to intestinal bacteria that may initiate mucosal inflammation in genetically susceptible individuals. Additional genes associated with the disease are recently being identified.

Wikipedia : 73 Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any segment of the... more...

Related Diseases for Crohn's Disease

Diseases related to Crohn's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1570)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 32.7 S100A9 S100A8 S100A12 NOD2 LACC1 ITGA4
2 ulcerative colitis 32.6 S100A12 NOD2 LACC1 IRGM CCR6
3 colitis 32.5 S100A12 NOD2 LACC1 IRGM CCR6
4 pouchitis 31.7 S100A9 NOD2
5 spondyloarthropathy 1 31.7 NOD2 HP CCR6
6 sarcoidosis 1 31.6 S100A9 NOD2 IL12RB2 CCR6
7 celiac disease 1 31.5 NOD2 IL18RAP HP CCR6
8 psoriasis 31.5 S100A9 S100A8 S100A12 NOD2 ITGA4 CCR6
9 inflammatory bowel disease 5 31.5 NOD2 IRGM CCR6
10 leprosy 3 31.1 NOD2 LACC1 IRGM IL12RB2 CCR6
11 juvenile rheumatoid arthritis 31.0 S100A9 S100A8 S100A12
12 inflammatory bowel disease 19 30.9 NOD2 IRGM
13 takayasu arteritis 30.9 S100A12 IL12RB2 HP
14 inflammatory bowel disease 1 30.8 PRKCQ NOD2 IRGM FMNL2 CCR6
15 inflammatory bowel disease 23 30.7 IL12RB2 CCR6
16 anorectal stricture 30.6 NOD2 IRGM
17 iritis 30.5 NOD2 CCR6
18 dry eye syndrome 30.4 S100A9 S100A8 CCR6
19 inflammatory bowel disease 18 30.4 NOD2 CCR6
20 inflammatory bowel disease 9 30.2 NOD2 CCR6
21 gastroduodenal crohn's disease 11.4
22 ileitis 11.3
23 melkersson-rosenthal syndrome 11.2
24 irritable bowel syndrome 11.2
25 orofacial granulomatosis 11.2
26 inflammatory bowel disease 29 11.2
27 ileocolitis 11.2
28 crohn's disease of the esophagus 11.2
29 diarrhea 11.1
30 short bowel syndrome 11.1
31 pyoderma gangrenosum 11.1
32 inflammatory bowel disease 13 11.1
33 inflammatory bowel disease 14 11.1
34 rickets 11.1
35 granulomatous disease, chronic, x-linked 11.1
36 hermansky-pudlak syndrome 5 11.1
37 autoinflammation, immune dysregulation, and eosinophilia 11.1
38 epidermolysis bullosa acquisita 11.0
39 hemorrhoid 11.0
40 colorectal cancer 11.0
41 keratomalacia 11.0
42 skin tag 11.0
43 inflammatory diarrhea 11.0
44 littoral cell angioma of the spleen 11.0
45 guillain-barre syndrome, familial 11.0
46 bile acid malabsorption, primary 11.0
47 autoimmune disease 6 11.0
48 stomach disease 11.0
49 crohn's colitis 10.9
50 colonic disease 10.9

Comorbidity relations with Crohn's Disease via Phenotypic Disease Network (PDN):

Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Inflammatory Bowel Disease 1
Intestinal Obstruction Protein-Energy Malnutrition
Ulcerative Colitis

Graphical network of the top 20 diseases related to Crohn's Disease:

Diseases related to Crohn's Disease

Symptoms & Phenotypes for Crohn's Disease

UMLS symptoms related to Crohn's Disease:

nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

MGI Mouse Phenotypes related to Crohn's Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 CCR6 HP IL12RB2 IL18BP IL18RAP INPP5D
2 homeostasis/metabolism MP:0005376 9.77 CCR6 CEP43 FMNL2 HP IL12RB2 IL18BP
3 immune system MP:0005387 9.36 CCR6 HP IL12RB2 IL18BP IL18RAP INPP5D

Drugs & Therapeutics for Crohn's Disease

Drugs for Crohn's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 904)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Norepinephrine Approved Phase 4 51-41-2 439260
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
parecoxib Approved Phase 4 198470-84-7
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Denosumab Approved Phase 4 615258-40-7
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616
Phenylephrine Approved Phase 4 59-42-7 6041
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
Deflazacort Approved, Investigational Phase 4 14484-47-0
Lactitol Approved, Investigational Phase 4 585-86-4 157355
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
Eslicarbazepine acetate Approved Phase 4 236395-14-5, 75970-99-9 123618
Citalopram Approved Phase 4 59729-33-8 2771
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
Nitric Oxide Approved Phase 4 10102-43-9 145068
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
Pantoprazole Approved Phase 4 102625-70-7 4679
Chromium Approved Phase 4 7440-47-3 27668
Copper Approved, Investigational Phase 4 7440-50-8 27099
Molybdenum Approved Phase 4 7439-98-7 185498
Iodine Approved, Investigational Phase 4 7553-56-2 807
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
Omalizumab Approved, Investigational Phase 4 242138-07-4
45 Artichoke Approved Phase 4
Trimethobenzamide Approved, Investigational Phase 4 138-56-7 5577
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
Demeclocycline Approved Phase 4 127-33-3 5311063
Ephedrine Approved Phase 4 299-42-3 9294

Interventional clinical trials:

(show top 50) (show all 3149)
# Name Status NCT ID Phase Drugs
1 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
2 Phase IV Study Comparing a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
3 A Randomized, Controlled, Single-blind Study of Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4 corticosteroid
4 Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, China Unknown status NCT03901937 Phase 4 ω-3 polyunsaturated fatty acid
5 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A Multi-center, Double Blinded, Randomized, Placebo Controlled Study Unknown status NCT01817426 Phase 4 Infliximab
6 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
7 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
8 Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
9 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
10 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
11 Does Clinical Response Correlate With Serum Certolizumab Levels? A Prospective Open Label Trial of Adult Patients With Active Crohn's Disease (APOLLO) Unknown status NCT02597829 Phase 4 Certolizumab Pegol
12 Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy Unknown status NCT01024647 Phase 4
13 The Effect of Probiotics on Bowel Disease Unknown status NCT01078935 Phase 4
14 Oxepa in Multiple Trauma: Prospective, Randomized, Comparative, Double-blind, Controlled Clinical Study Unknown status NCT01099501 Phase 4
15 Insulin Requirement for Pure- Protein Meal in Children With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion - a Cross-over, Randomized Trial. Unknown status NCT02685449 Phase 4 Insulin glulisine;Insulin aspart;Insulin lispro
16 Safety and Efficacy of Immunosuppression With Basiliximab, Delayed Dose Tacrolimus Plus Enteric Coated Mycophenolic Acid, Versus Standard Dose Tacrolimus, Enteric Coated Mycophenolic Acid Plus Corticosteroids in Patients Undergoing Orthotopic Liver Transplantation (OLT) Unknown status NCT02123108 Phase 4 Basiliximab
17 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
18 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
19 Immuno-enhanced Versus Standard Early Enteral Nutrition Use in Gastrointestinal Postoperative Patients Unknown status NCT01778166 Phase 4 Immuno-enhanced;Standard early enteral nutrition
20 The Comparison of Different Administration Routes of Pediatric Premedication-Single Center,Randomized,Controlled Trial Unknown status NCT02313337 Phase 4 Anesthesia induction(midazolam,fentanyl,propofol,atracurium);Anesthesia maintenance(midazolam,fentanyl,propofol,atracurium)
21 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
22 Randomized Double Blinded Trial to Investigate Effects of an Enteral Nutritional Supplement Enriched With Eicosapentaenoic Acid on Body Composition,Complications,Stress Response,Immune Function & Quality of Life in After Esophagectomy Unknown status NCT00790140 Phase 4
23 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
24 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Unknown status NCT01642875 Phase 4
25 Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke Unknown status NCT02643784 Phase 4 Rosuvastatin
26 Impact of Cyclosporine or Steroid Withdrawal at 3 Months Post Transplantation on Graft Function, Patient Survival and Cardiovascular Surrogate Markers the First 5 Years After Renal Transplantation. Unknown status NCT00903188 Phase 4 cyclosporine;Everolimus
27 Conversion From Multiple-Daily Dose Enteric-Coated Depakote to Once-Daily Depakote ER in Elderly Outpatients With Epilepsy or Behavioral Disturbances: Unknown status NCT00312676 Phase 4
28 Efficiency and Tolerance of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula in the Critically Ill Patient : a Prospective Randomized Trial Unknown status NCT01833624 Phase 4
29 Effect of Enteral Nutrition in the Outcome of Patients With Cardiovascular Surgery Unknown status NCT01432769 Phase 4
30 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
31 A Single Centre, Prospective, Open-Label, Parallel Group, Randomized Study to Compare the Gastrointestinal Tolerability of Mycophenolate Mofetil (MMF, CellCept) and Enteric-Coated Mycophenolate Sodium (EC-MPS, Myfortic) in Maintenance Transplant Patients Treated With Calcineurin Inhibitors Unknown status NCT00611494 Phase 4 MMF;EC-MPS
32 Comparison of Enteral Versus Intravenous Potassium Supplementation in Hypokalemia in Post Cardiac Surgery Pediatric Cardiac Intensive Care Patients - Prospective Open Label Randomized Control Trial Unknown status NCT02015962 Phase 4 Intravenous potassium chloride;Oral potassium chloride
33 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance, Tramadol PCA and Early Postoperative Enteral Nutrition in Patients After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
34 The Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection Followed by Diammonium Glycyrrhizinate Enteric-coated Capsules and Combined With Entecavir on the Treatment of Chronic Hepatitis B Unknown status NCT03349008 Phase 4 Entecavir;Magnesium Isoglycyrrhizinate;Diammonium Glycyrrhizinate;Magnesium Isoglycyrrhizinate Placebo;Diammonium Glycyrrhizinate Placebo
35 Absorption and Pharmacokinetics of Nitroglycerin as a Tablet or in the Form of Rapidly Degradable Capsule in Young Healthy Unknown status NCT03777605 Phase 4 Nitroglycerin 0.4 MG
36 The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation on the Number of Oocytes Obtained During IVF in Poor Ovarian Responders Unknown status NCT02357472 Phase 4 dehydroepiandrosterone
37 Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis. Unknown status NCT01067430 Phase 4 Etoricoxib;Diclofenac
38 Fast-track Surgery Recovery Program With Early Jejunostomy Nutrition Protocol Minimizes Time to Adjuvant Chemotherapy in Patients Undergoing Laparoscopic Gastrectomy for Gastric Cancer Unknown status NCT01766765 Phase 4
39 PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk. Unknown status NCT02970604 Phase 4 Aspirin
40 Open Label Prophylaxis Study of Lithium Plus Extended- Release Carbamazepine (Equetro®) Combination for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4 Lithium Plus Extended- Release Carbamazepine
41 The Use of Oral Naloxone to Prevent Post Spinal Fusion Ileus Unknown status NCT03176316 Phase 4 Naloxone
42 Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study Unknown status NCT01391221 Phase 4 Duloxetine
43 Prospective Controlled Protocol for 3 Months Steroid Withdrawal With Tacrolimus, Basiliximab, and Mycophenolate Mofetil in Renal Transplant Recipients Unknown status NCT01550445 Phase 4 Prednisolone
44 Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
45 Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial Completed NCT02256462 Phase 4 Adalimumab
46 A Randomized, Single Blinded, Controlled, Multi Center Phase 4 Study for Induction of Remission in Active Pediatric Crohn's Disease, Using 2 Months Antibiotic Course of Azithromycin Combined With Metronidazole vs. Metronidazole Alone. Completed NCT01596894 Phase 4 Azithromycin + Metronidazole;Metronidazole
47 Vitamin D in Pediatric Crohn's Disease Completed NCT01187459 Phase 4
49 Open-label Study on Small Bowel Lesions Suggestive of Crohn's Disease in Patients With Moderate to Severe Plaque Psoriasis Treated With Adalimumab Completed NCT01556672 Phase 4 Adalimumab
50 A Phase III, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren™ (Natalizumab) in Crohn's Disease Subjects Who Have Previously Participated in Antegren Crohn's Disease Studies Completed NCT00280956 Phase 4 natalizumab

Search NIH Clinical Center for Crohn's Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :

aminosalicylic acid

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Crohn's Disease cell therapies at LifeMap Discovery.

Genetic Tests for Crohn's Disease

Anatomical Context for Crohn's Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Crohn's Disease:


MalaCards organs/tissues related to Crohn's Disease:

Colon, Small Intestine, Liver, T Cells, Bone Marrow, Bone, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Crohn's Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Crohn's Disease

Articles related to Crohn's Disease:

(show top 50) (show all 33779)
# Title Authors PMID Year
De novo and rare mutations in the HSPA1L heat shock gene associated with inflammatory bowel disease. 6 61
28126021 2017
NOD2-associated autoinflammatory disease: a large cohort study. 61 6
26070941 2015
Dysfunctional Crohn's Disease-Associated NOD2 Polymorphisms Cannot be Reliably Predicted on the Basis of RIPK2 Binding or Membrane Association. 61 6
26500656 2015
Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. 61 6
21983784 2011
NOD2 exonic variations in Iranian Crohn's disease patients. 61 6
21274544 2011
Evaluation of 22 genetic variants with Crohn's disease risk in the Ashkenazi Jewish population: a case-control study. 61 6
21548950 2011
Genome-wide expression profiling identifies an impairment of negative feedback signals in the Crohn's disease-associated NOD2 variant L1007fsinsC. 6 61
21335489 2011
Genotyping for NOD2 genetic variants and crohn disease: a metaanalysis. 6 61
19713276 2009
Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review. 61 6
18718560 2009
Variants of CARD15, TNFA and PTPN22 and susceptibility to Crohn's disease in the Czech population: high frequency of the CARD15 1007fs. 6 61
18489434 2008
Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. 6 61
15770725 2005
Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. 6 61
15571588 2004
Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. 6 61
15198989 2004
NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? 61 6
15190267 2004
Crohn disease: frequency and nature of CARD15 mutations in Ashkenazi and Sephardi/Oriental Jewish families. 61 6
15024686 2004
Failure to replicate the association of the novel NOD2/CARD15 haplotype (S268P-JW1) to Crohn's disease in the Jewish Israeli population. 61 6
14765395 2004
A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews. 61 6
12577202 2003
Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. 61 6
12626759 2003
Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. 61 6
12512038 2003
CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. 6 61
12019468 2002
CARD15 mutations in Blau syndrome. 6 61
11528384 2001
Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. 6 61
11425413 2001
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. 61 6
11385577 2001
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. 61 6
11385576 2001
Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients. 61 42
33725990 2021
Localization of recurrent lesions following ileocolic resection for Crohn's disease. 42 61
33743665 2021
Two years follow-up of golimumab treatment in refractory enteropathic spondyloarthritis patients with Crohn disease: A STROBE-compliant study. 61 42
33761677 2021
A Case of Blau Syndrome with NOD2 E383K Mutation. 6
27339507 2016
Brief Report: First Identification of Intrafamilial Recurrence of Blau Syndrome due to Gonosomal NOD2 Mosaicism. 6
26606664 2016
Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. 6
25416713 2015
Ex vivo and in vitro production of pro-inflammatory cytokines in Blau syndrome. 6
25829188 2015
Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice. 6
25429073 2015
Blau syndrome polymorphisms in NOD2 identify nucleotide hydrolysis and helical domain 1 as signalling regulators. 6
25093298 2014
Ultrasonographic assessment reveals detailed distribution of synovial inflammation in Blau syndrome. 6
24713464 2014
Blau syndrome, the prototypic auto-inflammatory granulomatous disease. 6
25136265 2014
The intermediate filament protein, vimentin, is a regulator of NOD2 activity. 6
22684479 2013
Dermatitis as a characteristic phenotype of a new autoinflammatory disease associated with NOD2 mutations. 6
23102769 2013
NOD2/CARD15 gene mutation identified in a Chinese family with Blau syndrome. 6
22509093 2012
A new category of autoinflammatory disease associated with NOD2 gene mutations. 6
21914217 2011
Familial case of Blau syndrome associated with a CARD15/NOD2 mutation. 6
20565245 2010
Co-existence of chronic renal failure, renal clear cell carcinoma, and Blau syndrome. 6
20084402 2010
NOD2-associated diseases: Bridging innate immunity and autoinflammation. 6
19467619 2010
Sporadic Blau syndrome with onset of widespread granulomatous dermatitis in the newborn period. 6
20199415 2010
Incomplete penetrance of the NOD2 E383K substitution among members of a pediatric granulomatous arthritis pedigree. 6
19479836 2009
Monocyte-derived dendritic cells from Crohn patients show differential NOD2/CARD15-dependent immune responses to bacteria. 6
18240302 2008
Interstitial pneumonitis in Blau syndrome with documented mutation in CARD15. 6
17393391 2007
Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. 6
17207093 2006
Blau syndrome associated with a CARD15/NOD2 mutation. 6
17157607 2006
A new CARD15 mutation in Blau syndrome. 6
15812565 2005
Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. 6
15459013 2005

Variations for Crohn's Disease

ClinVar genetic disease variations for Crohn's Disease:

6 (show top 50) (show all 428)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HSPA1L NM_005527.4(HSPA1L):c.800C>T (p.Thr267Ile) SNV association 372133 rs139868987 GRCh37: 6:31778950-31778950
GRCh38: 6:31811173-31811173
2 HSPA1L NM_005527.4(HSPA1L):c.1673A>C (p.Glu558Ala) SNV association 372131 rs2227955 GRCh37: 6:31778077-31778077
GRCh38: 6:31810300-31810300
3 HSPA1L NM_005527.4(HSPA1L):c.229G>A (p.Gly77Ser) SNV association 372134 rs368138379 GRCh37: 6:31779521-31779521
GRCh38: 6:31811744-31811744
4 HSPA1L NM_005527.4(HSPA1L):c.515_517del (p.Leu172del) Deletion association 372135 rs750447828 GRCh37: 6:31779233-31779235
GRCh38: 6:31811456-31811458
5 HSPA1L NM_005527.4(HSPA1L):c.802G>A (p.Ala268Thr) SNV association 372132 rs34620296 GRCh37: 6:31778948-31778948
GRCh38: 6:31811171-31811171
6 NOD2 NM_001370466.1(NOD2):c.2938dup (p.Leu980fs) Duplication association 4691 rs2066847 GRCh37: 16:50763778-50763779
GRCh38: 16:50729867-50729868
7 NOD2 NM_001370466.1(NOD2):c.2474A>G (p.Asn825Ser) SNV association 97856 rs104895467 GRCh37: 16:50750810-50750810
GRCh38: 16:50716899-50716899
8 NOD2 NM_001370466.1(NOD2):c.2023C>T (p.Arg675Trp) SNV association 4693 rs2066844 GRCh37: 16:50745926-50745926
GRCh38: 16:50712015-50712015
9 NOD2 NM_001370466.1(NOD2):c.2633+1G>A SNV Pathogenic 998262 GRCh37: 16:50753920-50753920
GRCh38: 16:50720009-50720009
10 NOD2 NM_001370466.1(NOD2):c.920G>A (p.Arg307Gln) SNV Pathogenic 4694 rs104895461 GRCh37: 16:50744823-50744823
GRCh38: 16:50710912-50710912
11 NOD2 NM_001370466.1(NOD2):c.1066G>A (p.Glu356Lys) SNV Pathogenic 4701 rs104895477 GRCh37: 16:50744969-50744969
GRCh38: 16:50711058-50711058
12 NOD2 NM_001370466.1(NOD2):c.919C>T (p.Arg307Trp) SNV Pathogenic 4696 rs104895462 GRCh37: 16:50744822-50744822
GRCh38: 16:50710911-50710911
13 NOD2 NM_001370466.1(NOD2):c.1639C>T (p.Gln547Ter) SNV Pathogenic 634817 rs1264862631 GRCh37: 16:50745542-50745542
GRCh38: 16:50711631-50711631
14 NOD2 NM_001370466.1(NOD2):c.1457T>C (p.Met486Thr) SNV Pathogenic 97834 rs104895473 GRCh37: 16:50745360-50745360
GRCh38: 16:50711449-50711449
15 PRKCQ NM_006257.5(PRKCQ):c.989C>T (p.Pro330Leu) SNV Pathogenic 586982 rs2236379 GRCh37: 10:6527143-6527143
GRCh38: 10:6485181-6485181
16 NOD2 NM_001370466.1(NOD2):c.2717+158C>T SNV risk factor 4697 rs5743289 GRCh37: 16:50756774-50756774
GRCh38: 16:50722863-50722863
17 NOD2 NM_001370466.1(NOD2):c.2938dup (p.Leu980fs) Duplication risk factor 4691 rs2066847 GRCh37: 16:50763778-50763779
GRCh38: 16:50729867-50729868
18 NOD2 NM_001370466.1(NOD2):c.2641G>C (p.Gly881Arg) SNV risk factor 4692 rs2066845 GRCh37: 16:50756540-50756540
GRCh38: 16:50722629-50722629
19 FMNL2 NM_052905.4(FMNL2):c.407T>C (p.Leu136Pro) SNV Likely pathogenic 997783 GRCh37: 2:153415301-153415301
GRCh38: 2:152558787-152558787
20 NOD2 NM_001370466.1(NOD2):c.2291G>A (p.Arg764Gln) SNV Conflicting interpretations of pathogenicity 97850 rs104895464 GRCh37: 16:50746194-50746194
GRCh38: 16:50712283-50712283
21 NOD2 NM_001370466.1(NOD2):c.485C>T (p.Thr162Met) SNV Conflicting interpretations of pathogenicity 319431 rs61755182 GRCh37: 16:50741791-50741791
GRCh38: 16:50707880-50707880
22 NOD2 NM_001370466.1(NOD2):c.850C>T (p.Arg284Trp) SNV Conflicting interpretations of pathogenicity 97885 rs104895427 GRCh37: 16:50744753-50744753
GRCh38: 16:50710842-50710842
23 NOD2 NM_001370466.1(NOD2):c.1922C>T (p.Pro641Leu) SNV Uncertain significance 319456 rs5743275 GRCh37: 16:50745825-50745825
GRCh38: 16:50711914-50711914
24 NOD2 NM_001370466.1(NOD2):c.552C>T (p.Ala184=) SNV Uncertain significance 319432 rs5743269 GRCh37: 16:50741858-50741858
GRCh38: 16:50707947-50707947
25 NOD2 NM_001370466.1(NOD2):c.193G>A (p.Val65Ile) SNV Uncertain significance 319425 rs187264529 GRCh37: 16:50733599-50733599
GRCh38: 16:50699688-50699688
26 NOD2 NM_001370466.1(NOD2):c.59C>T (p.Ser20Leu) SNV Uncertain significance 319424 rs201586544 GRCh37: 16:50733465-50733465
GRCh38: 16:50699554-50699554
27 NOD2 NM_001370466.1(NOD2):c.2066G>A (p.Arg689His) SNV Uncertain significance 319460 rs200035357 GRCh37: 16:50745969-50745969
GRCh38: 16:50712058-50712058
28 NOD2 NM_001370466.1(NOD2):c.59C>T (p.Ser20Leu) SNV Uncertain significance 319424 rs201586544 GRCh37: 16:50733465-50733465
GRCh38: 16:50699554-50699554
29 NOD2 NM_001370466.1(NOD2):c.193G>T (p.Val65Phe) SNV Uncertain significance 660017 rs187264529 GRCh37: 16:50733599-50733599
GRCh38: 16:50699688-50699688
30 NOD2 NM_001370466.1(NOD2):c.616C>T (p.Gln206Ter) SNV Uncertain significance 849868 GRCh37: 16:50744519-50744519
GRCh38: 16:50710608-50710608
31 NOD2 NM_001370466.1(NOD2):c.1235G>A (p.Arg412His) SNV Uncertain significance 319444 rs143110172 GRCh37: 16:50745138-50745138
GRCh38: 16:50711227-50711227
32 NOD2 NM_001370466.1(NOD2):c.726G>A (p.Pro242=) SNV Uncertain significance 319436 rs369766454 GRCh37: 16:50744629-50744629
GRCh38: 16:50710718-50710718
33 NOD2 NM_001370466.1(NOD2):c.1211C>T (p.Ser404Leu) SNV Uncertain significance 97826 rs104895431 GRCh37: 16:50745114-50745114
GRCh38: 16:50711203-50711203
34 NOD2 NM_001370466.1(NOD2):c.1923del (p.His642fs) Deletion Uncertain significance 863734 GRCh37: 16:50745826-50745826
GRCh38: 16:50711915-50711915
35 NOD2 NM_001370466.1(NOD2):c.845T>C (p.Leu282Pro) SNV Uncertain significance 934684 GRCh37: 16:50744748-50744748
GRCh38: 16:50710837-50710837
36 NOD2 NM_001370466.1(NOD2):c.659G>T (p.Cys220Phe) SNV Uncertain significance 936769 GRCh37: 16:50744562-50744562
GRCh38: 16:50710651-50710651
37 NOD2 NM_001370466.1(NOD2):c.2605C>T (p.Arg869Ter) SNV Uncertain significance 938415 GRCh37: 16:50753891-50753891
GRCh38: 16:50719980-50719980
38 NOD2 NM_001370466.1(NOD2):c.1529C>T (p.Pro510Leu) SNV Uncertain significance 948438 GRCh37: 16:50745432-50745432
GRCh38: 16:50711521-50711521
39 NOD2 NM_001370466.1(NOD2):c.2971C>T (p.Leu991Phe) SNV Uncertain significance 955794 GRCh37: 16:50765659-50765659
GRCh38: 16:50731748-50731748
40 NOD2 NM_001370466.1(NOD2):c.1118C>T (p.Pro373Leu) SNV Uncertain significance 956010 GRCh37: 16:50745021-50745021
GRCh38: 16:50711110-50711110
41 NOD2 NM_001370466.1(NOD2):c.449C>T (p.Pro150Leu) SNV Uncertain significance 956771 GRCh37: 16:50733855-50733855
GRCh38: 16:50699944-50699944
42 NOD2 NM_001370466.1(NOD2):c.1087G>A (p.Asp363Asn) SNV Uncertain significance 957653 GRCh37: 16:50744990-50744990
GRCh38: 16:50711079-50711079
43 NOD2 NM_001370466.1(NOD2):c.2363G>T (p.Gly788Val) SNV Uncertain significance 970293 GRCh37: 16:50746266-50746266
GRCh38: 16:50712355-50712355
44 NOD2 NM_001370466.1(NOD2):c.1459T>C (p.Tyr487His) SNV Uncertain significance 449632 rs540122692 GRCh37: 16:50745362-50745362
GRCh38: 16:50711451-50711451
45 NOD2 NM_001370466.1(NOD2):c.617A>C (p.Gln206Pro) SNV Uncertain significance 531596 rs369098290 GRCh37: 16:50744520-50744520
GRCh38: 16:50710609-50710609
46 NOD2 NM_001370466.1(NOD2):c.1109C>T (p.Pro370Leu) SNV Uncertain significance 531599 rs150078153 GRCh37: 16:50745012-50745012
GRCh38: 16:50711101-50711101
47 NOD2 NM_001370466.1(NOD2):c.2845G>A (p.Ala949Thr) SNV Uncertain significance 531609 rs148561632 GRCh37: 16:50759443-50759443
GRCh38: 16:50725532-50725532
48 NOD2 NM_001370466.1(NOD2):c.1097G>A (p.Arg366His) SNV Uncertain significance 566850 rs140918872 GRCh37: 16:50745000-50745000
GRCh38: 16:50711089-50711089
49 NOD2 NM_001370466.1(NOD2):c.1679G>A (p.Arg560His) SNV Uncertain significance 570145 rs373185098 GRCh37: 16:50745582-50745582
GRCh38: 16:50711671-50711671
50 NOD2 NM_001370466.1(NOD2):c.1745T>G (p.Phe582Cys) SNV Uncertain significance 649658 rs777798807 GRCh37: 16:50745648-50745648
GRCh38: 16:50711737-50711737

Copy number variations for Crohn's Disease from CNVD:

7 (show all 25)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 19625 1 150839831 150840116 Deletion and duplication LCE3C Crohn''s disease
2 19631 1 150852910 150853198 Deletion and duplication LCE3B Crohn''s disease
3 71426 12 69818942 132349534 Copy number Crohn''s disease
4 112709 17 40930407 78774742 Copy number Crohn''s disease
5 139336 2 179004449 242951149 Copy number Crohn''s disease
6 194979 5 147200000 152100000 Low copy numbers IRGM Crohn''s disease
7 195288 5 149800000 152700000 Copy number Crohn''s disease
8 195354 5 150157836 180857866 Copy number Crohn''s disease
9 195374 5 150183562 180857866 Copy number Crohn''s disease
10 195384 5 150207878 150208422 Deletion IRGM Crohn''s disease
11 195385 5 150207878 150208422 Deletion and duplication IRGM Crohn''s disease
12 210788 6 31416574 170899992 Copy number Crohn''s disease
13 211338 6 32582950 170899992 Copy number Crohn''s disease
14 211384 6 32609209 170899992 Copy number Crohn''s disease
15 211736 6 336751 356443 Copy number IRF4 Crohn''s disease
16 230702 8 1 12700000 Copy number Crohn''s disease
17 241420 8 6200000 12700000 Copy number DEFB4A Crohn''s disease
18 241431 8 6200000 12700000 Duplication DEFB103A Crohn''s disease
19 241433 8 6200000 12700000 Duplication DEFB4A Crohn''s disease
20 241436 8 6200000 12700000 Duplication SPAG11B Crohn''s disease
21 241467 8 6200000 12700000 Low copy numbers Crohn''s disease
22 242030 8 6873390 6875823 Copy number Crohn''s disease
23 242532 8 7259842 7791647 Copy number DEFB4A Crohn''s disease
24 242534 8 7259842 7791647 Deletion and duplication DEFB4A Crohn''s disease
25 242535 8 7259842 7791647 Deletion and duplication DEFB4A Crohn''s disease

Expression for Crohn's Disease

LifeMap Discovery
Genes differentially expressed in tissues of Crohn's Disease patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 REG1A regenerating family member 1 alpha Colon + 4.42 0.002
2 CXCL2 C-X-C motif chemokine ligand 2 Colon + 4.02 0.000
3 REG1B regenerating family member 1 beta Colon + 3.99 0.008
4 LCN2 lipocalin 2 Colon + 3.90 0.000
5 REG3A regenerating family member 3 alpha Colon + 3.74 0.026
6 CXCL11 C-X-C motif chemokine ligand 11 Colon + 3.70 0.016
7 CXCL1 C-X-C motif chemokine ligand 1 Colon + 3.60 0.000
8 CXCL8 C-X-C motif chemokine ligand 8 Colon + 3.50 0.004
9 DEFA6 defensin alpha 6 Colon + 3.49 0.029
10 S100A8 S100 calcium binding protein A8 Colon + 3.04 0.017
Search GEO for disease gene expression data for Crohn's Disease.

Pathways for Crohn's Disease

Pathways related to Crohn's Disease according to KEGG:

# Name Kegg Source Accession
1 NOD-like receptor signaling pathway hsa04621
2 Cytokine-cytokine receptor interaction hsa04060
3 JAK-STAT signaling pathway hsa04630
4 Inflammatory bowel disease hsa05321
5 Autophagy - animal hsa04140

Pathways related to Crohn's Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
13.03 S100A9 S100A8 S100A12 PRKCQ NOD2 ITGA4
Show member pathways
3 11.03 ITGA4 IL12RB2 CCR6

GO Terms for Crohn's Disease

Cellular components related to Crohn's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.73 S100A9 S100A8 S100A12 PRKCQ NOD2 ITGA4
2 secretory granule lumen GO:0034774 8.8 S100A9 S100A8 S100A12

Biological processes related to Crohn's Disease according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 10.01 S100A9 S100A8 S100A12 HP CEACAM6
2 innate immune response GO:0045087 10 S100A9 S100A8 S100A12 NOD2 LACC1 IRGM
3 defense response GO:0006952 9.84 SP140 NOD2 IRGM HP
4 positive regulation of inflammatory response GO:0050729 9.81 S100A9 S100A8 S100A12
5 positive regulation of cell growth GO:0030307 9.8 S100A9 S100A8 CEP43
6 response to lipopolysaccharide GO:0032496 9.8 S100A9 S100A8 NOD2 IL18BP IL12RB2
7 defense response to bacterium GO:0042742 9.8 S100A9 S100A8 S100A12 NOD2 IRGM HP
8 neutrophil chemotaxis GO:0030593 9.79 S100A9 S100A8 S100A12
9 cellular response to cytokine stimulus GO:0071345 9.77 ITGA4 IL18RAP IL18BP
10 regulation of inflammatory response GO:0050727 9.73 S100A9 S100A8 NOD2 LACC1
11 inflammatory response GO:0006954 9.7 S100A9 S100A8 S100A12 PRKCQ LACC1 IRGM
12 defense response to fungus GO:0050832 9.67 S100A9 S100A8 S100A12
13 positive regulation of stress-activated MAPK cascade GO:0032874 9.65 NOD2 IL26
14 positive regulation of interleukin-17 production GO:0032740 9.64 PRKCQ NOD2
15 astrocyte development GO:0014002 9.64 S100A9 S100A8
16 acute inflammatory response GO:0002526 9.63 S100A8 HP
17 cytokine production GO:0001816 9.63 S100A9 S100A8 S100A12
18 chronic inflammatory response GO:0002544 9.61 S100A9 S100A8
19 immune system process GO:0002376 9.61 S100A9 S100A8 S100A12 PRKCQ NOD2 LACC1
20 autocrine signaling GO:0035425 9.6 S100A9 S100A8
21 interleukin-18-mediated signaling pathway GO:0035655 9.58 IL18RAP IL18BP
22 chemokine production GO:0032602 9.58 S100A9 S100A8
23 peptidyl-cysteine S-nitrosylation GO:0018119 9.57 S100A9 S100A8
24 cytokine production involved in immune response GO:0002367 9.56 NOD2 LACC1
25 pattern recognition receptor signaling pathway GO:0002221 9.55 NOD2 LACC1
26 leukocyte migration involved in inflammatory response GO:0002523 9.54 S100A9 S100A8 CCR6
27 sequestering of zinc ion GO:0032119 9.51 S100A9 S100A8
28 neutrophil aggregation GO:0070488 9.48 S100A9 S100A8
29 nucleotide-binding oligomerization domain containing 2 signaling pathway GO:0070431 9.43 NOD2 LACC1 IRGM
30 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.1 S100A9 S100A8 S100A12 PRKCQ NOD2 IL18RAP

Molecular functions related to Crohn's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium-dependent protein binding GO:0048306 9.43 S100A9 S100A8 S100A12
2 CARD domain binding GO:0050700 9.32 NOD2 IRGM
3 arachidonic acid binding GO:0050544 9.16 S100A9 S100A8
4 Toll-like receptor 4 binding GO:0035662 8.96 S100A9 S100A8
5 RAGE receptor binding GO:0050786 8.8 S100A9 S100A8 S100A12

Sources for Crohn's Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....